Biotech & Health

5 ways biotech startups can mitigate risk to grow sustainably in the long run

Comment

Multicolored strings attached together; 5 ways risk management
Image Credits: jayk7 (opens in a new window) / Getty Images

Omar Khalil

Contributor

Omar Khalil is a partner at Santé Ventures, where he focuses primarily on biotechnology and medical technology companies.

The unprecedented explosion of investment in life sciences over the past decade has resulted in incredible new therapies for patients, strong financial returns for companies and an overall increase in translational research, which is critical to advancing the next generation of therapies. It has also led to eye-popping levels of capital raised by early-stage companies, some of which were years away from entering the clinic with their first product.

Naturally, a generous flow of financing generates excitement for everyone involved. Capital is the fuel that advances scientific and technological innovation, and it means a life science startup can create products that benefit the world at large.

But what happens when the funding suddenly dries up?

In the world of biotech, for example, it’s extremely capital intensive to develop multiple products that are all going through clinical trials simultaneously. The infrastructure needed to maintain these different programs can be too unwieldy to weather a financial drought.

A better approach would be to focus on a lead program — a single product that they can take through various stages of development, ultimately leading to FDA approval. In fact, lead programs validate the value of an underlying platform, enabling companies to raise capital through licensing and partnerships.

There will always be ebbs and flows in funding, so here are five ways life science startups can optimize for success regardless of the economic climate.

Don’t confuse successful fundraising with a successful company

At the end of the day, fundraising is a means to an end. The mission for most life science startups is to improve patient outcomes. However, science is hard, and cash in the bank does not overcome the complexities of human biology. Plenty of companies have successfully raised significant amounts of capital but were never successful in developing a beneficial product, therapy or technology.

While not a perfect proxy, the value at which a venture-backed company exits (through M&A or IPO) can be an indication of its success in developing a new product. However, there is practically no correlation between the amount of capital a company raises and its ultimate exit value.

Since 2010, the R-squared between exit value and total invested capital — a measure of how correlated the two variables are — for all healthcare exits is a paltry 0.34. When you drill down to a correlation between the exit value and the amount of capital raised in a company’s Series A financing, it drops to a practically negligible value of 0.05, according to PitchBook.

These statistics support the notion that just because a company raises significant amounts of capital (especially early on), there is no guarantee of a successful investment outcome.

Founders shouldn’t let peer pressure or investor check size mandates dictate their financing strategy. Instead, focus on advancing your program through the key stages of technical and clinical development.

This enables more capital to be raised over time and, ultimately, more value to be created for shareholders.

Maintain strategic focus over optionality

While management teams and investors like to have “multiple shots on goal” to increase their chances of success, the lack of a singular focus can lead to heavy cash burn. Too many resources are needed to run multiple programs in parallel. Instead, it’s important to remember that the vast majority of a biotech company’s value is driven by its lead program. Especially early in a company’s lifecycle, the strength and progress of the lead product often drives both investor and strategic (i.e., Big Pharma) interest.

Don’t spread your limited capital across several programs too early. Instead, avoid distractions and direct the flow of resources to your company’s most valuable priority.

In my own portfolio, I’ve seen startups make the mistake of taking on too much, too quickly. Eager to demonstrate the broad potential of their technology, CEOs will quickly ramp up hiring and development activities for multiple programs. However, these companies were later unable to raise subsequent rounds due to both market- and company-specific factors. This led to drastic cuts, including employee layoffs and project cancellations with key vendors.

Such cuts can be devastating for company culture and morale, and when managed ineffectively, can cause a downward spiral that doesn’t end well. Thankfully, our companies have had the strong leadership necessary to get through the challenges successfully, but they didn’t get through that without significant scarring.

Validate your platform

Of course, a company launching with option value and the potential for generating multiple clinical programs presents an attractive profile. However, that optionality should not come at the expense of putting the lead program at risk.

Any new platform technology should be validated, and it’s only truly validated when a program derived from that platform demonstrates a clinically meaningful effect.

The success of a lead program justifies increased investment in other programs. Few companies can overcome the failure of a lead program to successfully advance other products.

New technology platforms are typically more capital intensive to scale, due to the novelty of the development and manufacturing processes. Key to success here is to ensure the technology has been validated and sufficient value has been demonstrated to lower the company’s cost of capital for building and scaling up manufacturing operations. The increased scale can then help advance subsequent programs at an even faster rate than if they were pursued from the beginning.

Identify true value inflection milestones

A detailed and realistic development plan is foundational for any life science startup. It’s also vital to integrate that development plan with a thoughtful financing strategy.

Founders should identify and externally validate meaningful milestones that will lead to technical validation or risk mitigation of the program to provide the guideposts for their company’s capital needs.

While it’s important to have contingency funds (typically six-12 months of additional runway), raising substantially more capital can lead to unhealthy growth. Conversely, raising too little capital means there will be more rounds of fundraising.

Figuring out the sweet spot of how much capital the company needs to increase the likelihood of success while avoiding the challenges of overcapitalization is among the most important exercises for a new venture. Management teams should validate those milestones through conversations with their investors, advisers and industry partners.

One of the most critical mistakes I’ve made when working with an emerging life sciences tech company was believing “if you build it, they will come.” Despite customer skepticism about the space, our team convinced ourselves that clinical proof-of-concept data would be sufficient to generate market interest.

Deeper exploration would have identified at least two additional milestones related to manufacturing and regulatory development that were critical for driving interest. While our team was able to raise the capital to achieve the additional milestones, greater validation upfront would have led to a stronger, more comprehensive development plan.

Stay disciplined

It’s often said that life science startups can be incredibly successful while never generating a profit (and often, never even generating any revenue). That means they will always be reliant on external financing for everyday operations — capital that can be very expensive for existing shareholders.

Founders must remember to stay disciplined about expense management, even when capital availability is high. You need a cushion if and when capital becomes more limited in the future.

Even for companies who are awash in cash, prioritize the program’s critical path while limiting the temptation to allocate resources against “pet projects” or purely academic exercises.

The life science venture ecosystem is adjusting to a significant slowdown in financing volume and velocity after several record-breaking years. It’s still too early to know whether this is a short-term correction, or if it’s a new normal that will be maintained for the foreseeable future. However, by following the five strategies above, entrepreneurs can be better prepared for whatever comes next.

More TechCrunch

When it comes to the world of venture-backed startups, some issues are universal, and some are very dependent on where the startups and its backers are located. It’s something we…

The ups and downs of investing in Europe, with VCs Saul Klein and Raluca Ragab

Welcome back to TechCrunch’s Week in Review — TechCrunch’s newsletter recapping the week’s biggest news. Want it in your inbox every Saturday? Sign up here. OpenAI announced this week that…

Scarlett Johansson brought receipts to the OpenAI controversy

Accurate weather forecasts are critical to industries like agriculture, and they’re also important to help prevent and mitigate harm from inclement weather events or natural disasters. But getting forecasts right…

Deal Dive: Can blockchain make weather forecasts better? WeatherXM thinks so

pcTattletale’s website was briefly defaced and contained links containing files from the spyware maker’s servers, before going offline.

Spyware app pcTattletale was hacked and its website defaced

Featured Article

Synapse, backed by a16z, has collapsed, and 10 million consumers could be hurt

Synapse’s bankruptcy shows just how treacherous things are for the often-interdependent fintech world when one key player hits trouble. 

19 hours ago
Synapse, backed by a16z, has collapsed, and 10 million consumers could be hurt

Sarah Myers West, profiled as part of TechCrunch’s Women in AI series, is managing director at the AI Now institute.

Women in AI: Sarah Myers West says we should ask, ‘Why build AI at all?’

Keeping up with an industry as fast-moving as AI is a tall order. So until an AI can do it for you, here’s a handy roundup of recent stories in the world…

This Week in AI: OpenAI and publishers are partners of convenience

Evan, a high school sophomore from Houston, was stuck on a calculus problem. He pulled up Answer AI on his iPhone, snapped a photo of the problem from his Advanced…

AI tutors are quietly changing how kids in the US study, and the leading apps are from China

Welcome to Startups Weekly — Haje‘s weekly recap of everything you can’t miss from the world of startups. Sign up here to get it in your inbox every Friday. Well,…

Startups Weekly: Drama at Techstars. Drama in AI. Drama everywhere.

Last year’s investor dreams of a strong 2024 IPO pipeline have faded, if not fully disappeared, as we approach the halfway point of the year. 2024 delivered four venture-backed tech…

From Plaid to Figma, here are the startups that are likely — or definitely — not having IPOs this year

Federal safety regulators have discovered nine more incidents that raise questions about the safety of Waymo’s self-driving vehicles operating in Phoenix and San Francisco.  The National Highway Traffic Safety Administration…

Feds add nine more incidents to Waymo robotaxi investigation

Terra One’s pitch deck has a few wins, but also a few misses. Here’s how to fix that.

Pitch Deck Teardown: Terra One’s $7.5M Seed deck

Chinasa T. Okolo researches AI policy and governance in the Global South.

Women in AI: Chinasa T. Okolo researches AI’s impact on the Global South

TechCrunch Disrupt takes place on October 28–30 in San Francisco. While the event is a few months away, the deadline to secure your early-bird tickets and save up to $800…

Disrupt 2024 early-bird tickets fly away next Friday

Another week, and another round of crazy cash injections and valuations emerged from the AI realm. DeepL, an AI language translation startup, raised $300 million on a $2 billion valuation;…

Big tech companies are plowing money into AI startups, which could help them dodge antitrust concerns

If raised, this new fund, the firm’s third, would be its largest to date.

Harlem Capital is raising a $150 million fund

About half a million patients have been notified so far, but the number of affected individuals is likely far higher.

US pharma giant Cencora says Americans’ health information stolen in data breach

Attention, tech enthusiasts and startup supporters! The final countdown is here: Today is the last day to cast your vote for the TechCrunch Disrupt 2024 Audience Choice program. Voting closes…

Last day to vote for TC Disrupt 2024 Audience Choice program

Featured Article

Signal’s Meredith Whittaker on the Telegram security clash and the ‘edge lords’ at OpenAI 

Among other things, Whittaker is concerned about the concentration of power in the five main social media platforms.

2 days ago
Signal’s Meredith Whittaker on the Telegram security clash and the ‘edge lords’ at OpenAI 

Lucid Motors is laying off about 400 employees, or roughly 6% of its workforce, as part of a restructuring ahead of the launch of its first electric SUV later this…

Lucid Motors slashes 400 jobs ahead of crucial SUV launch

Google is investing nearly $350 million in Flipkart, becoming the latest high-profile name to back the Walmart-owned Indian e-commerce startup. The Android-maker will also provide Flipkart with cloud offerings as…

Google invests $350 million in Indian e-commerce giant Flipkart

A Jio Financial unit plans to purchase customer premises equipment and telecom gear worth $4.32 billion from Reliance Retail.

Jio Financial unit to buy $4.32B of telecom gear from Reliance Retail

Foursquare, the location-focused outfit that in 2020 merged with Factual, another location-focused outfit, is joining the parade of companies to make cuts to one of its biggest cost centers –…

Foursquare just laid off 105 employees

“Running with scissors is a cardio exercise that can increase your heart rate and require concentration and focus,” says Google’s new AI search feature. “Some say it can also improve…

Using memes, social media users have become red teams for half-baked AI features

The European Space Agency selected two companies on Wednesday to advance designs of a cargo spacecraft that could establish the continent’s first sovereign access to space.  The two awardees, major…

ESA prepares for the post-ISS era, selects The Exploration Company, Thales Alenia to develop cargo spacecraft

Expressable is a platform that offers one-on-one virtual sessions with speech language pathologists.

Expressable brings speech therapy into the home

The French Secretary of State for the Digital Economy as of this year, Marina Ferrari, revealed this year’s laureates during VivaTech week in Paris. According to its promoters, this fifth…

The biggest French startups in 2024 according to the French government

Spotify is notifying customers who purchased its Car Thing product that the devices will stop working after December 9, 2024. The company discontinued the device back in July 2022, but…

Spotify to shut off Car Thing for good, leading users to demand refunds

Elon Musk’s X is preparing to make “likes” private on the social network, in a change that could potentially confuse users over the difference between something they’ve favorited and something…

X should bring back stars, not hide ‘likes’

The FCC has proposed a $6 million fine for the scammer who used voice-cloning tech to impersonate President Biden in a series of illegal robocalls during a New Hampshire primary…

$6M fine for robocaller who used AI to clone Biden’s voice